E. Levchenko

7.5k total citations · 2 hit papers
75 papers, 908 citations indexed

About

E. Levchenko is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, E. Levchenko has authored 75 papers receiving a total of 908 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in E. Levchenko's work include Lung Cancer Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Immunotherapy and Biomarkers (13 papers). E. Levchenko is often cited by papers focused on Lung Cancer Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Immunotherapy and Biomarkers (13 papers). E. Levchenko collaborates with scholars based in Russia, United States and Germany. E. Levchenko's co-authors include Evgeny N. Imyanitov, Aglaya G. Iyevleva, Salma K. Jabbour, Alex Martínez‐Martí, Baerin Houghton, Ki Hyeong Lee, Jean-Baptiste Paoli, Dariusz M. Kowalski, В. В. Бредер and Takefumi Komiya and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

E. Levchenko

55 papers receiving 881 citations

Hit Papers

Molecular testing and targeted therapy for non-small cell... 2020 2026 2022 2024 2020 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
    2020 339 citations E. Levchenko et al. profile →
  2. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
    2021 162 citations Salma K. Jabbour, Ki Hyeong Lee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Levchenko Russia 12 510 451 341 178 147 75 908
Erin Larkins United States 14 637 1.2× 441 1.0× 286 0.8× 162 0.9× 116 0.8× 28 937
Shakun Malik United States 18 454 0.9× 455 1.0× 316 0.9× 259 1.5× 83 0.6× 35 993
Francesca Casaluce Italy 15 512 1.0× 462 1.0× 326 1.0× 140 0.8× 82 0.6× 38 841
Elena Poddubskaya Russia 16 478 0.9× 269 0.6× 312 0.9× 236 1.3× 129 0.9× 57 846
Anna Minchom United Kingdom 19 697 1.4× 605 1.3× 343 1.0× 154 0.9× 118 0.8× 110 1.1k
Regula Deurloo Switzerland 5 468 0.9× 215 0.5× 316 0.9× 222 1.2× 153 1.0× 12 947
Gonzalo Recondo United States 15 637 1.2× 576 1.3× 386 1.1× 313 1.8× 103 0.7× 54 1.1k
Joyce Cheng United States 13 596 1.2× 370 0.8× 244 0.7× 229 1.3× 84 0.6× 31 943
Sharon B. Sams United States 17 514 1.0× 208 0.5× 382 1.1× 229 1.3× 134 0.9× 40 1.0k
Ken Uchibori Japan 15 567 1.1× 614 1.4× 360 1.1× 156 0.9× 67 0.5× 59 885

Countries citing papers authored by E. Levchenko

Since Specialization
Citations

This map shows the geographic impact of E. Levchenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Levchenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Levchenko more than expected).

Fields of papers citing papers by E. Levchenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Levchenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Levchenko. The network helps show where E. Levchenko may publish in the future.

Co-authorship network of co-authors of E. Levchenko

This figure shows the co-authorship network connecting the top 25 collaborators of E. Levchenko. A scholar is included among the top collaborators of E. Levchenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Levchenko. E. Levchenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Pircher, Andreas, Michael A. W. Eaton, Atsushi Hata, et al.. (2024). 117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study. Immuno-Oncology Technology. 24. 100746–100746. 3 indexed citations
5.
Semiglazova, Т. Yu., et al.. (2023). Study of the Effectiveness of Personalized Rehabilitation for Resectable Lung Cancer Patients. Voprosy Onkologii. 69(5). 908–916. 1 indexed citations
6.
Vm, Merabishvili, et al.. (2023). The need for types of inpatient treatment and budget forecasting for lung cancer patients with a first established diagnosis. SHILAP Revista de lepidopterología. 3(1). 20–29.
7.
Levchenko, E., et al.. (2023). Operative approaches for thymectomy: clinical characteristics and classification variant. Bulletin of the Russian Military Medical Academy. 25(3). 505–514. 1 indexed citations
8.
Felip, Enriqueta, Eric Vallières, C.Z. Zhou, et al.. (2021). LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. Annals of Oncology. 32. S1319–S1319. 8 indexed citations
9.
Levchenko, E., et al.. (2019). ADVANCED LARYNGEAL CANCER (LITERATURE REVIEW). SHILAP Revista de lepidopterología. 18(5). 97–107. 1 indexed citations
10.
Levchenko, E., et al.. (2019). Chondrosarcoma of trachea: case report of successful surgical treatment of local recurrence. SHILAP Revista de lepidopterología. 9(2). 95–98. 1 indexed citations
11.
Levchenko, E., et al.. (2019). Surgical management of hypopharyngeal cancer (narrative review). SHILAP Revista de lepidopterología. 9(2). 35–42. 2 indexed citations
12.
Semiglazova, Т. Yu., et al.. (2019). PHYSICAL METHODS OF REHABILITATION IN PATIENTS WITH LUNG CANCER: A SCIENTOMETRIC ANALYSIS OF EVIDENCE-BASED RESEARCH. Voprosy Onkologii. 65(4). 575–583. 2 indexed citations
13.
Staa, Tjeerd van, et al.. (2019). ISOLATED PULMONARY METASTASES: EVOLUTION OF THE TREATMENT TECHNOLOGIES. Voprosy Onkologii. 65(5). 645–652.
14.
Pérol, M., Solange Peters, Nick Pavlakis, et al.. (2018). 138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology. 13(4). S80–S81. 1 indexed citations
15.
16.
Levchenko, E., et al.. (2017). LONG-TERM RESULTS OF BRONCHOPLASTIC SURGICAL INTERVENTIONS IN COMPARISON WITH PNEUMONECTOMIES IN LUNG CANCER. Voprosy Onkologii. 63(2). 234–239. 4 indexed citations
17.
Levchenko, E., et al.. (2017). MARKERS OF SURGERY STRESS IN COMPARISON OF THORACOSCOPIC AND THORACOTOMIC RESECTIONS IN LUNG CANCER. Voprosy Onkologii. 63(2). 199–207. 2 indexed citations
18.
Levchenko, E., et al.. (2017). COMPARATIVE ASSESSMENT OF PAIN AND LIFE QUALITY IN THE PATIENTS AFTER OPEN AND VIDEO-ASSISTED LOBECTOMY FOR LUNG CANCER. Messenger of Anesthesiology and Resuscitation. 14(6). 57–64.
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erin Larkins Breakdown of academic impact, for papers by Shakun Malik Breakdown of academic impact, for papers by Francesca Casaluce Breakdown of academic impact, for papers by Elena Poddubskaya Breakdown of academic impact, for papers by Anna Minchom Breakdown of academic impact, for papers by Regula Deurloo Breakdown of academic impact, for papers by Gonzalo Recondo Breakdown of academic impact, for papers by Joyce Cheng Breakdown of academic impact, for papers by Sharon B. Sams Breakdown of academic impact, for papers by Ken Uchibori
Rankless by CCL
2026